成立年份: 1998
总资产(USD): 不愿意公开
员工总人数: 500以上
主要竞争优势: 品牌,国际认证/标准,经验丰富的研发人员,生产能力,合同定制,良好的信誉,优质服务
其他竞争优势:
专利与版权: US, EU, Australia, Russia, China, Japan, and Korea: molecular chaperone technology China: Glargine crystallization technology
业务类型: 制造商,出口商
年销售额(USD): 不愿意公开
主要销售市场: 北美洲,中/南美洲,西欧,东欧,亚洲,中东,非洲
主要产品类别: 原料药,生物制品,药品制剂
所有产品: 1.Insulin: a. Basalin®(insulin glargine injection) b. Prandilin™(insulin lispro injection) c. Prandilin™25R(insulin lispro 25R injection) d. Rapilin®(insulin aspart injection) e. Rapilin®30(insulin aspart 30 injection) f. Similin®30(insulin human 30 injection) 2.Medical Device: a. GanleePen™(insulin pen) b. GanleeFine®(pen needle)
外销比重:
内销比重:
主要客户:
合同定制:
付款条款:
Founded in 1998, Gan & Lee Pharmaceuticals is a leading biopharmaceutical company in China specializing in the development, production, and commercialization of insulin analogs and supporting medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters and nearly 3000 employees. With state-of-the-art buildings and GMP facilities, Gan & Lee has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.
1998 - Developed China’s first recombinant human insulin
2001 - Developed China's first fast-acting insulin analog (lispro)
2002 - Developed China’s first long-acting insulin analog (glargine) and first premixed insulin analog (lispro 25)
2009 - Developed China’s first insulin pen
2013 - Developed second generation insulin pen
2014 - Founded US subsidiary - Gan & Lee Pharmaceuticals USA
2015 - Initiated phase I clinical trial on insulin glargine in Germany
2017 - Initiated phase III clinical trials on insulin glargine in the USA and EU
2019 - Initiated phase I clinical trials on insulin lispro and aspart in the USA and EU
2020 - Initially listed on the A-share index on the Shanghai Stock Exchange
2021 - Completed phase I clinical trials on insulin glargine in Germany
北京市通州区漷县镇南凤西一路8号